Andecaliximab
Monoclonal antibody
- none
- 1518996-49-0
- none
- 571045EIM4
- D11262
Andecaliximab (INN;[1] development code GS-5745) is an experimental humanized monoclonal antibody designed for the treatment of cancer and inflammatory diseases.
This drug was developed by Gilead Sciences, Inc.[2]
Phase II and phase III trials for gastric cancer or gastroesophageal junction adenocarcinoma completed in 2019.
References
- v
- t
- e